58596-88-6

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dichloro-3-methyl-5-nitropyridine is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2,6-Dichloro-3-methyl-5-nitropyridine is employed as an intermediate for the production of pesticides and other agrochemicals. Its properties contribute to the creation of effective solutions for pest control and crop protection.
Used in Organic Synthesis:
2,6-Dichloro-3-methyl-5-nitropyridine is utilized as a building block in organic synthesis, particularly for the preparation of heterocyclic compounds. Its versatile structure enables the development of a wide range of chemical compounds with diverse applications in various industries.
Safety Precautions:
Due to its hazardous nature, it is crucial to handle 2,6-Dichloro-3-methyl-5-nitropyridine with care. It is essential to work in a well-ventilated area and use appropriate personal protective equipment, such as gloves, goggles, and masks, to minimize the risk of skin, eye, and respiratory irritation. Proper handling and storage of 2,6-Dichloro-3-methyl-5-nitropyridine are necessary to ensure the safety of individuals working with it.

Upstream product

• 58584-94-4 2,6-dichloro-3-methylpyridine 
• 56961-78-5 2,4-dichloro-5-methylpyridine 
• 1241373-24-9 2-chloro-5-methyl-3-nitropyridine 1-oxide 
• 18368-64-4 2-chloro-5-methylpyridine 
• 18368-76-8 2 chloro-3-methylpyridine 
• 23056-40-8 2-chloro-5-methyl-3-nitro-pyridine 
• 91668-83-6 2-Chloro-3-methylpyridine N-oxide 
• 20173-49-3 2-chloro-5-methylpyridine-N-oxide 
• 22280-56-4 2-chloro-3-methyl-5-nitropyridine 

Downstream Products

• 1258884-09-1 6-chloro-N-(2-fluoro-4-iodophenyl)-5-methyl-3-nitropyridin-2-amine 
• 177278-96-5 6-Chloro-5-methyl-3-nitro-2-(2-oxo-cyclohexyl)-pyridine 
• 202217-19-4 6-chloro-5-methyl-3-nitropyridin-2-amine 

Relevant academic research and scientific papers

Sulfide Analogues of Flupirtine and Retigabine with Nanomolar KV7.2/KV7.3 Channel Opening Activity

The potassium channel openers flupirtine and retigabine have proven to be valuable analgesics or antiepileptics. Their recent withdrawal due to occasional hepatotoxicity and tissue discoloration, respectively, leaves a therapeutic niche unfilled. Metabolic oxidation of both drugs gives rise to the formation of electrophilic quinones. These elusive, highly reactive metabolites may induce liver injury in the case of flupirtine and blue tissue discoloration after prolonged intake of retigabine. We examined which structural features can be altered to avoid the detrimental oxidation of the aromatic ring and shift oxidation toward the formation of more benign metabolites. Structure–activity relationship studies were performed to evaluate the KV7.2/3 channel opening activity of 45 derivatives. Sulfide analogues were identified that are devoid of the risk of quinone formation, but possess potent KV7.2/3 opening activity. For example, flupirtine analogue 3-(3,5-difluorophenyl)-N-(6-(isobutylthio)-2-(pyrrolidin-1-yl)pyridin-3-yl)propanamide (48) has 100-fold enhanced activity (EC50=1.4 nm), a vastly improved toxicity/activity ratio, and the same efficacy as retigabine in vitro.

Flupirtine and retigabine as templates for ligand-based drug design of KV7.2/3 activators

Drug induced liver injury (DILI) and tissue discoloration led to the recent discontinuation of the therapeutic use of the closely related drugs flupirtine and retigabine, respectively. Experience gained with these drugs strongly suggests that heterotetramer, voltage-gated potassium channels 2 and 3 (KV7.2/3) are valid targets for effective treatment of pain and epilepsy. Because the adverse effects are not related to the mechanism of action, it appears promising to investigate chemical modifications of these clinically validated, drug-like leads. In the present retro-metabolic drug design study, a series of 43 compounds were synthesized and characterized with regard to KV7.2/3 opening activity and efficacy. The most active compound 22d displays excellent potency (EC50 = 4 nM) and efficacy (154%) as a KV7.2/3 opener. Limited aqueous solubility hampered toxicity testing at concentrations higher than 63 μM, but this concentration was nontoxic to two hepatocellular cell lines (HEP-G2 and TAMH) in culture. The slightly less active but more soluble compound 25b (EC50 = 11 nM, efficacy 111%) showed an improved toxicity/activity ratio compared to flupirtine by three orders of magnitude and represents an attractive lead structure for the development of safer analgesics and antiepileptics.

NITROGENATED HETEROCYCLIC COMPOUND

The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

NOVEL 6-ARYLAMINO PYRIDONE SULFONAMIDES AND 6-ARYLAMINO PYRAZINONE SULFONAMIDES AS MEK INHIBITORS

The invention provides novel substituted 6-arylamino pyridone sulfonamides and 6 arylamino pyrazinone sulfonamides represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans

SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR MEDICAL USE

The present application discloses novel substituted 1,4-oxazepanyl-pyridine derivatives and their use as modulators of the voltage gated KV7 (KCNQ) potassium ion channels. In other aspects the application discloses the use of these compounds, i

IMIDAZOPYRIDINE COMPOUND

A compound represented by the following general formula (1), or a salt or hydrate thereof: wherein R1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R2 represents a hydrogen atom or a C1-C6 alkyl group, R3 represents methyl or ethyl group, R4 represents a C1-C6 alkyl group, R5 represents a hydrogen atom, provided that a compound wherein R1 is a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and R2 is a hydrogen atom is excluded.